CIK 0001404644
- Non-accelerated filer
- Smaller reporting company
Neurogene Inc.
Sign in to watch- Ticker
- NGNE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 980542593
- Phone
- +1 877-237-5020
- Business address
- 535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
- Former names
- Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 38 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-04-02 | Redmile Group, LLC 10% owner | Purchase | +38,300 | $11.36 | $435K | 4,050,045 |
| 2020-04-02 | Redmile Group, LLC 10% owner | Purchase | +1,000 | $11.85 | $12K | 4,051,045 |
| 2020-04-02 | Redmile Group, LLC 10% owner | Sale | −9,734 | $11.30 | $110K | 4,041,311 |
| 2020-04-02 | Redmile Group, LLC 10% owner | Sale | −100 | $11.82 | $1K | 4,041,211 |
| 2020-04-01 | Redmile Group, LLC 10% owner | Purchase | +33,500 | $10.95 | $367K | 4,012,579 |
| 2020-04-01 | Redmile Group, LLC 10% owner | Purchase | +9,000 | $11.65 | $105K | 4,021,579 |
| 2020-04-01 | Redmile Group, LLC 10% owner | Sale | −9,634 | $11.06 | $107K | 4,011,945 |
| 2020-04-01 | Redmile Group, LLC 10% owner | Sale | −200 | $11.87 | $2K | 4,011,745 |
| 2020-03-31 | Redmile Group, LLC 10% owner | Purchase | +22,500 | $10.18 | $229K | 3,971,579 |
| 2020-03-31 | Redmile Group, LLC 10% owner | Purchase | +7,500 | $10.71 | $80K | 3,979,079 |
| 2020-03-30 | Redmile Group, LLC 10% owner | Purchase | +29,800 | $9.91 | $295K | 3,946,379 |
| 2020-03-30 | Redmile Group, LLC 10% owner | Purchase | +2,700 | $10.27 | $28K | 3,949,079 |
| 2020-03-27 | Redmile Group, LLC 10% owner | Purchase | +50,000 | $9.21 | $460K | 3,916,579 |
| 2020-03-16 | Ho Robert Chief Financial Officer | Grant or award · Restricted Stock Units | +75,000 | 75,000 | ||
| 2020-03-16 | Ho Robert Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2019-12-20 | BAKER BROS. ADVISORS LP Director | Purchase | +250,037 | $8.40 | $2.1M | 1,450,557 |
| 2019-12-20 | BAKER BROS. ADVISORS LP Director | Purchase | +2,767,505 | $8.40 | $23.2M | 12,872,664 |
| 2019-12-20 | BAKER BROS. ADVISORS LP Director | Returned to the company | −1,160,148 | 290,409 | ||
| 2019-12-20 | BAKER BROS. ADVISORS LP Director | Returned to the company | −9,765,333 | 3,107,331 | ||
| 2019-12-20 | BAKER BROS. ADVISORS LP Director | Grant or award · Pre-funded Warrants | +1,160,148 | 1,161,048 |
Page 11 of 20 · 397 trades